Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

FDA PMA

Joint, temporomandibular, implant

PMA Number: P980052 · 2026-03-06

ApplicantStryker Leibinger, GmbH & Co KG
Decision Date2026-03-06
PMA NumberP980052
Product CodeLZD
Device ClassClass 3
Medical SpecialtyD
Regulation Number21 CFR 8
Advisory CommitteeDE

Device Summary

Joint, temporomandibular, implant is the device name listed in this FDA 510(k) record. The listed applicant is Stryker Leibinger, GmbH & Co KG. It received FDA 510(k) clearance on 2026-03-06. The device is classified under product code LZD. It was reviewed by the DE advisory panel.

Frequently Asked Questions

What is the Joint, temporomandibular, implant?

Joint, temporomandibular, implant is a medical device that received FDA 510(k) clearance on 2026-03-06. The listed applicant is Stryker Leibinger, GmbH & Co KG.

When did Joint, temporomandibular, implant receive FDA 510(k) clearance?

The clearance date for Joint, temporomandibular, implant can be found in the official FDA records.

Who is the listed applicant for Joint, temporomandibular, implant?

The FDA 510(k) record lists Stryker Leibinger, GmbH & Co KG as the applicant. This does not by itself establish the device manufacturer.

What is the FDA product code for Joint, temporomandibular, implant?

The FDA product code for Joint, temporomandibular, implant is LZD.

Related Clinical Trials

Related records are matched automatically using names, product codes, or other metadata. A match does not establish a verified clinical, scientific, corporate, or regulatory relationship; review the linked official sources.

NCT07608549FLASH Pilot Phase 1 Safety StudyNOT_YET_RECRUITINGNCT06562205PAP Systems External Clinical Studies (ECS)NOT_YET_RECRUITINGNCT04745156A Study Using Brain Stimulation and Behavioral Therapy to Increase Extent of Resection in Low-Grade GliomasNOT_YET_RECRUITINGNCT06443177The Effect of Sympathetic Modulation on Cerebral Vasospasm Secondary to Aneurysmal Subarachnoid HemorrhageSUSPENDED

Official Source

View on FDA Database →

Data sourced from FDA Open API. For the most current and authoritative information, always refer to the official record.

↑